A team of investigators at Children’s Hospital Los Angeles (CHLA) has unveiled OncoKids, an advanced sequencing-based panel particularly designed for paediatric cancers.

OncoKids can be used to guide the diagnosis and treatment of cancer in a child based on the genomic alterations specific to the child’s tumour.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The sequencing-based panel was developed by a team comprising laboratory geneticists, oncologists and pathologists.

OncoKids helps detect mutations, gene amplification and gene fusions for a complete range of pediatric cancers, including leukaemia, bone and soft tissue tumours and brain tumours.

CHLA Children's Center for Cancer and Blood Diseases director Dr Alan Wayne said: “For those children whose cancer comes back or does not respond to standard therapy, this advanced genomic analysis can help us determine the next best step.

See Also:

“By identifying the specific mutations associated with an individual's cancer, we can better select treatment options that might be most effective.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test can be conducted using a small amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) (20ng) isolated from fresh, frozen or formalin-fixed paraffin-embedded tissue, so that retrospective analysis of primary and recurrent tumours can be done.

The combined DNA and RNA can help replace many of the single gene, or more narrowly-focused, advanced sequencing-based panels, in addition to a wide range of fluorescence in situ hybridisation assays, which will save time and preserve tissue.

Developed with Thermo Fisher Scientific, the OncoKids panel uses the Ion Torrent S5 sequencing platform and Ion AmpliSeq technology.